ZA200204492B - Heterocyclic derivatives. - Google Patents

Heterocyclic derivatives.

Info

Publication number
ZA200204492B
ZA200204492B ZA200204492A ZA200204492A ZA200204492B ZA 200204492 B ZA200204492 B ZA 200204492B ZA 200204492 A ZA200204492 A ZA 200204492A ZA 200204492 A ZA200204492 A ZA 200204492A ZA 200204492 B ZA200204492 B ZA 200204492B
Authority
ZA
South Africa
Prior art keywords
heterocyclic derivatives
heterocyclic
derivatives
Prior art date
Application number
ZA200204492A
Inventor
Alessandra Orlandi
Original Assignee
Glaxosmithkline Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Spa filed Critical Glaxosmithkline Spa
Publication of ZA200204492B publication Critical patent/ZA200204492B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
ZA200204492A 1999-12-08 2002-06-05 Heterocyclic derivatives. ZA200204492B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9929037.1A GB9929037D0 (en) 1999-12-08 1999-12-08 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
ZA200204492B true ZA200204492B (en) 2004-06-30

Family

ID=10865952

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200204492A ZA200204492B (en) 1999-12-08 2002-06-05 Heterocyclic derivatives.

Country Status (30)

Country Link
US (2) US6713491B2 (en)
EP (1) EP1237886B1 (en)
JP (1) JP4311901B2 (en)
KR (1) KR100788579B1 (en)
CN (1) CN1325488C (en)
AR (1) AR030923A1 (en)
AT (1) ATE323691T1 (en)
AU (1) AU769232B2 (en)
BR (1) BR0016235A (en)
CA (1) CA2393303C (en)
CO (1) CO5251474A1 (en)
CY (1) CY1106105T1 (en)
CZ (1) CZ301052B6 (en)
DE (1) DE60027461T2 (en)
DK (1) DK1237886T3 (en)
ES (1) ES2257343T3 (en)
GB (1) GB9929037D0 (en)
HK (1) HK1047436B (en)
HU (1) HUP0203650A3 (en)
IL (2) IL150010A0 (en)
MX (1) MXPA02005802A (en)
MY (1) MY129892A (en)
NO (1) NO323263B1 (en)
PL (1) PL356713A1 (en)
PT (1) PT1237886E (en)
TN (1) TNSN00240A1 (en)
TR (1) TR200201503T2 (en)
TW (1) TW524804B (en)
WO (1) WO2001042238A1 (en)
ZA (1) ZA200204492B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1619190B1 (en) * 2003-04-25 2010-12-29 Nippon Chemiphar Co., Ltd. Salts of (2s,3s)-3- [[(1s)-1-isobutoxymethyl-3-methylbutyl]carbamoyl] oxirane-2-carboxylic acid
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
LT3056492T (en) * 2004-10-08 2022-01-25 Abbvie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
EP2286800A1 (en) * 2005-04-11 2011-02-23 Abbott Laboratories Pharmaceutical compositions having improved dissolution profiles for poorly soluble drugs
BR112014009910B1 (en) * 2011-10-25 2020-06-30 Janssen Pharmaceutica N.V. 1- (5,6-dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt, pharmaceutical composition and topical ointment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
US6413959B1 (en) * 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
TR199800531T1 (en) 1995-09-29 1998-06-22 Glaxo Wellcome Spa Tetrahydroquinolines as NMDA antagonists.
GB9617305D0 (en) 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
AU2006001A (en) 2001-06-18
DE60027461T2 (en) 2006-09-28
CA2393303C (en) 2009-10-20
CN1407980A (en) 2003-04-02
US20030008899A1 (en) 2003-01-09
DK1237886T3 (en) 2006-08-14
EP1237886A1 (en) 2002-09-11
KR100788579B1 (en) 2007-12-26
HUP0203650A2 (en) 2003-03-28
NO20022682D0 (en) 2002-06-06
CZ20021981A3 (en) 2003-01-15
NO20022682L (en) 2002-07-17
KR20020086854A (en) 2002-11-20
NO323263B1 (en) 2007-02-19
TNSN00240A1 (en) 2002-05-30
HUP0203650A3 (en) 2004-01-28
TW524804B (en) 2003-03-21
JP4311901B2 (en) 2009-08-12
CN1325488C (en) 2007-07-11
ES2257343T3 (en) 2006-08-01
PL356713A1 (en) 2004-06-28
JP2003516403A (en) 2003-05-13
IL150010A0 (en) 2002-12-01
IL150010A (en) 2009-09-01
CO5251474A1 (en) 2003-02-28
GB9929037D0 (en) 2000-02-02
US6943176B2 (en) 2005-09-13
TR200201503T2 (en) 2002-10-21
AR030923A1 (en) 2003-09-03
HK1047436A1 (en) 2003-02-21
AU769232B2 (en) 2004-01-22
US20040162313A1 (en) 2004-08-19
WO2001042238A1 (en) 2001-06-14
HK1047436B (en) 2006-07-21
PT1237886E (en) 2006-07-31
CZ301052B6 (en) 2009-10-21
EP1237886B1 (en) 2006-04-19
CY1106105T1 (en) 2011-06-08
US6713491B2 (en) 2004-03-30
MXPA02005802A (en) 2004-08-12
CA2393303A1 (en) 2001-06-14
BR0016235A (en) 2002-08-27
ATE323691T1 (en) 2006-05-15
MY129892A (en) 2007-05-31
DE60027461D1 (en) 2006-05-24

Similar Documents

Publication Publication Date Title
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
HK1051695A1 (en) N6 heterocyclic 8-modified andenosine derivatives.
HK1041885A1 (en) Amide derivatives.
ZA200203003B (en) N-substituted carbamoyloxyalkyl-azolium derivatives.
GC0000183A (en) 3-Phenyl-pyridine derivatives
ZA200109595B (en) 13-methyl-erythromycin derivatives.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
HK1046400A1 (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
HK1044940A1 (en) Isoxazolecarboxamide derivatives
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
MXPA01012041A (en) Indole derivatives.
MXPA00011504A (en) Substituted heterocyclic derivatives.
HK1049161A1 (en) Indole derivatives.
GB0026485D0 (en) ›-Carboline derivatives
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
HK1048638A1 (en) Cyclopenteneone derivatives
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
AP2001002327A0 (en) 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
ZA200204492B (en) Heterocyclic derivatives.
MXPA01011285A (en) Thio-oxindole derivatives.
GB9929038D0 (en) Heterocyclic derivatives
GB9903337D0 (en) Heterocyclic derivatives
ZA200107632B (en) Thio-oxindole derivatives.
ZA993232B (en) Arylthiazolidinedione derivatives.